Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06037187 · ClinicalTrials.gov registry record
Coagulopathy of Immunodermatologic Diseases
A clinical trial of Autoimmune Bullous Dermatosis, sponsored by University of Nebraska.
- Recruiting
- Registry status
- 39
- Enrollment target
- 1
- Study location
NCT06037187: Recruiting study of Autoimmune Bullous Dermatosis, sponsored by University of Nebraska.
NCT06037187 is a study of Autoimmune Bullous Dermatosis that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 39 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06037187, a study of Autoimmune Bullous Dermatosis, is actively recruiting participants, sponsored by University of Nebraska.
- RECRUITING
- Registry status
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and mild/latent/well-controlled immune-mediated skin diseases. A one-time sample from 15 general dermatology outpatients who do not have a known or suspected diagnosis of bullous diseases, immune-mediated dermatologic condition, or cutaneous malignancy will also be collected to serve as control. Blood samples from both participant populations will be analyzed for coagulation and inflammatory markers and compared. The results of this study may help inform future studies on the utility of analyzing coagulation and fibrinolysis profiles of patients with autoimmune skin diseases.
Primary Outcome
Thromboelastography is a viscoelastic hemostatic assay that measures the global viscoelastic properties of whole blood clot formation under low shear stress.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood Draw
Study Locations (1)
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-05-09 |
| Est. Completion | 2025-12 |
What NCT06037187 shows while recruiting
NCT06037187 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 1 condition, with Autoimmune Bullous Dermatosis appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT06037187 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT06037187 about?
NCT06037187 is a clinical study titled "Coagulopathy of Immunodermatologic Diseases". This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and mild/latent/well-controlled immune-mediated skin diseases. A one-time sample fro...
What is the current status of trial NCT06037187?
This trial is currently recruiting. The enrollment target is 39 participants. The study started on 2023-05-09. Estimated completion is 2025-12.
What conditions does trial NCT06037187 study?
This clinical trial studies the following conditions: Autoimmune Bullous Dermatosis.
What interventions are being tested in trial NCT06037187?
The interventions under investigation include: Blood Draw (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06037187?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06037187 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI